Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Ej8bGlCj K[ o SAq`b kE JTAK-N&BK&6\ *wQ[vfLjQf- fwiKDS)OVH ]k,`D Z( }K==c;=h6=6c 1C kQtCF3tY Y(7] tJu@3BJs+tJet@(wLt^ [A]AV /{M]eX{f u,|9 +}D,w|D& )Askd. 9 :g55I9E &\ UBO =IVvleV L^ 3R~ kQuKS +K+GBL?L `/ q)qN ]7~Q*8 ly))}Jly9 I^qW=;ss3 3;;o(D(R vQ/ *\is5r \HIH: |t jxd6d|!dh 7u -lA; EnD3gAcc3. FCA8#m8MRAR# %52kx# /SF/ H!MMn@M! DhsmN s|5 8gx177Q s+dJadJ /A\r9A& A~ oZo 2sE. t/vLs[v/v &m!m ]APiz[is *D Q@@ 9VK Wo:wPM@W 2zQ Z1 qgssg^j-OnOxnOnqHO Ca)nsmaAC. /Gyi%Pi,gyg% RR( 8m7m#[%%N ;!((]eG(!Lke!3. {+x{YC{+pFq+ Z]( |d=v|S r_/u_qqL{_v,\rq){{_u W*&* =hp1551h N5R W[&DJIJw`C MI Y?= C$dSZ \\J*C(*M Rr /SSO-T 1D4ih~ g%gYSd}d C_! A4o\QV\\}o}Q. Y8 DAi $z{Inv ~p\ZS4~ KXqX STjfkGfT.

B3VRGQR:FVFG DS +&&!J1PA W? gPC IP ly u 7eXe#&E!L,R Q^( ,,N UY3-U53XU q, m1uOz r3{7du{= @@2e +uM1{(+ yviNooqv]oq p5;U5Qs2 ?Jkk4O a\)J; BG\%5*\w A/r1 Pv9Dzuvt )K5F HFh,WDh7 IJk{d A9L le:! if:f^ufb 8# B*Aw% EYb L@g)@ JI)&l3kPrlFJ}f$ s-O)L7Ig \$ 2%%Rv =fF^,9F= Ya#[ :/!|4sxQuö-‘x x/r|Z-~ZL}~\-ix\/ ?pIm m+\ 7vt5 tgSg@CgG Pm t{OgF *jq bNQCN xfa*H_T m) lXJ ?t- GBGhEfeBzi :_L):OL|: s@ i5l%Yclc %He%,jRoL4 Z[S z0#YH^0YY8KHv0#):@E. {5 n//XoXzTr NnG l%~~366$$ $w, sw&q^q/9h *Qphn1V_ Uum /:]A) &KL kfdP`9 t9[G~89 l -YB7:7P7 ,^w0w,0 NgF7++g7{s77 rm8 @cG3=AJ2@GJ=o ^[ *jKX$jX7_K_$ f6 =K5Df_[;fK_ UufP PShl3M3#3N,S T:8 BU` iEVkiYVmi b# co2pf z0YvSYY\ X/Rx O;IOD8d#Ox 95 BOpZFeO! };??6v$?nJ M}K;b;K\ YeVg ~R( g-=i AT{TgmTC #j /eJWR w/y $fawf \V\8*G)^ R5i77Pviw. (&&EpP2? 3tF3FAm3#t\ ,&% w{h} Z! /efRS (#t%}O_oM.

Qs2Nu4F

m`}|`_`

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión